Skip to main content
High RiskFDAfda-F-2147-2017PRODUCT QUALITY

BULK PRODUCT: MYPROTEIN, MYPRE Europe Base, bulk powder used for further processing in Europe

Category
Units Affected
39,600
Recall Date
March 23, 2017
Issuing Agency
Hazard
Product Quality

FDA Recall Notice

Source: U.S. Food and Drug Administration (FDA) — official FDA notice for recall FDA-F-2147-2017.

A raw material initially failed testing Staphylococcus aureus. A retest was conducted with passing results but an out of specification investigation was not properly conducted leaving concern that the finished product could contain the bacterium.

Corrective Action (per FDA)

Source: U.S. Food and Drug Administration (FDA) — official FDA notice for recall FDA-F-2147-2017.

Recall terminated by FDA.

✅ What you should do

  1. Stop using the product if you own it.
  2. Check the model number, lot code, or sell-by date against the recall notice above.
  3. Contact Armada Nutrition or the retailer where you bought it for a refund, replacement, or repair.
  4. For the most current official instructions, visit the FDA recall page.
  5. If you've been hurt by this product, report the incident to FDA.

Consumer Contact (per FDA)

Source: U.S. Food and Drug Administration (FDA) — official FDA notice for recall FDA-F-2147-2017.

Armada Nutrition

FDA

About the U.S. Food and Drug Administration

The FDA regulates drugs, medical devices, food, cosmetics, and tobacco. Adverse event reports and recall notices are the main public safety signal.

Visit FDA.gov →

📣 Report a food, supplement, or cosmetic problem to the FDA

If you had a reaction, found contamination, or experienced a labeling problem with this product, report it to the FDA. The agency uses consumer reports to track emerging safety signals and trigger recalls.

How to report to FDAFile a report at FDA

Armada Nutrition Recall FAQ

Armada Nutrition is the subject of a food safety report: BULK PRODUCT: MYPROTEIN, MYPRE Europe Base, bulk powder used for further processing in Europe. The notice was published on March 23, 2017 by the U.S. Food and Drug Administration (FDA). Approximately 39,600 units are potentially affected.